Abstract
We enrolled 479 patients with subarachnoid hemorrhage in a multicenter, randomized, double-blind placebo-controlled trial to determine whether treatment with the antifibrinolytic agent tranexamic acid improves outcome by preventing rebleeding. All three months there was no statistical difference between the outcomes in the tranexamic acid group and the control group. Of the 173 patients who died, 84 had received tranexamic acid and 89 placebo (95 per cent confidence interval for the difference in mortality rate, - 6 to 11 per cent). Similarly, when analysis was restricted to patients with an angiographically demonstrated aneurysm, there was no significant difference between the groups. This absence of effect was not due to a lack of antifibrinolytic action, since the rate of rebleeding was reduced from 24 per cent in the control group to 9 per cent in the tranexamic acid-treated group (chi-square = 18.07, P < 0.001), but resulted from a concurrent increase in the incidence of ischemic complications (15 per cent in the control group and 24 per cent in the tranexamic acid group; chi-square = 8.07, P < 0.01). We conclude that until some method can be found to minimize ischemic complications, tranexamic acid is of no benefit in patients with subarachnoid hemorrhage.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 432-437 |
| Number of pages | 6 |
| Journal | New England Journal of Medicine |
| Volume | 311 |
| Issue number | 7 |
| State | Published - 1984 |
| Externally published | Yes |
Fingerprint
ASJC Scopus subject areas
- Medicine(all)
Cite this
Antifibrinolytic treatment in subarachnoid hemorrhage. / Vermeulen, M.; Lindsay, K. W.; Murray, G. D.; Cheah, F.; Hijdra, A.; Muizelaar, Jan Paul; Schannong, M.; Teasdale, G. M.; van Crevel, H.; van Gijn, J.
In: New England Journal of Medicine, Vol. 311, No. 7, 1984, p. 432-437.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Antifibrinolytic treatment in subarachnoid hemorrhage
AU - Vermeulen, M.
AU - Lindsay, K. W.
AU - Murray, G. D.
AU - Cheah, F.
AU - Hijdra, A.
AU - Muizelaar, Jan Paul
AU - Schannong, M.
AU - Teasdale, G. M.
AU - van Crevel, H.
AU - van Gijn, J.
PY - 1984
Y1 - 1984
N2 - We enrolled 479 patients with subarachnoid hemorrhage in a multicenter, randomized, double-blind placebo-controlled trial to determine whether treatment with the antifibrinolytic agent tranexamic acid improves outcome by preventing rebleeding. All three months there was no statistical difference between the outcomes in the tranexamic acid group and the control group. Of the 173 patients who died, 84 had received tranexamic acid and 89 placebo (95 per cent confidence interval for the difference in mortality rate, - 6 to 11 per cent). Similarly, when analysis was restricted to patients with an angiographically demonstrated aneurysm, there was no significant difference between the groups. This absence of effect was not due to a lack of antifibrinolytic action, since the rate of rebleeding was reduced from 24 per cent in the control group to 9 per cent in the tranexamic acid-treated group (chi-square = 18.07, P < 0.001), but resulted from a concurrent increase in the incidence of ischemic complications (15 per cent in the control group and 24 per cent in the tranexamic acid group; chi-square = 8.07, P < 0.01). We conclude that until some method can be found to minimize ischemic complications, tranexamic acid is of no benefit in patients with subarachnoid hemorrhage.
AB - We enrolled 479 patients with subarachnoid hemorrhage in a multicenter, randomized, double-blind placebo-controlled trial to determine whether treatment with the antifibrinolytic agent tranexamic acid improves outcome by preventing rebleeding. All three months there was no statistical difference between the outcomes in the tranexamic acid group and the control group. Of the 173 patients who died, 84 had received tranexamic acid and 89 placebo (95 per cent confidence interval for the difference in mortality rate, - 6 to 11 per cent). Similarly, when analysis was restricted to patients with an angiographically demonstrated aneurysm, there was no significant difference between the groups. This absence of effect was not due to a lack of antifibrinolytic action, since the rate of rebleeding was reduced from 24 per cent in the control group to 9 per cent in the tranexamic acid-treated group (chi-square = 18.07, P < 0.001), but resulted from a concurrent increase in the incidence of ischemic complications (15 per cent in the control group and 24 per cent in the tranexamic acid group; chi-square = 8.07, P < 0.01). We conclude that until some method can be found to minimize ischemic complications, tranexamic acid is of no benefit in patients with subarachnoid hemorrhage.
UR - http://www.scopus.com/inward/record.url?scp=0021213657&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0021213657&partnerID=8YFLogxK
M3 - Article
VL - 311
SP - 432
EP - 437
JO - New England Journal of Medicine
JF - New England Journal of Medicine
SN - 0028-4793
IS - 7
ER -